A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.
Moore, Kathleen N
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. [electronic resource] - Future oncology (London, England) Jan 2018 - 123-136 p. digital
Publication Type: Journal Article; Review
1744-8301
10.2217/fon-2017-0379 doi
Antibodies, Monoclonal, Humanized--therapeutic use
Drug Resistance, Neoplasm--genetics
Female
Folate Receptor 1--antagonists & inhibitors
Humans
Immunoconjugates--immunology
Maytansine--analogs & derivatives
Ovarian Neoplasms--drug therapy
Platinum--adverse effects
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. [electronic resource] - Future oncology (London, England) Jan 2018 - 123-136 p. digital
Publication Type: Journal Article; Review
1744-8301
10.2217/fon-2017-0379 doi
Antibodies, Monoclonal, Humanized--therapeutic use
Drug Resistance, Neoplasm--genetics
Female
Folate Receptor 1--antagonists & inhibitors
Humans
Immunoconjugates--immunology
Maytansine--analogs & derivatives
Ovarian Neoplasms--drug therapy
Platinum--adverse effects